These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 22238936

  • 1. [Endocrine therapy for postmenopausal breast cancer (role of cycline D1)].
    Manikhas AG, Skvortsov VA, Manikhas GM, Raskin GA, Oganesian AS, Shemerovskiĭ AK.
    Vopr Onkol; 2011; 57(5):641-4. PubMed ID: 22238936
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Changing concepts of hormone receptor-positive advanced breast cancer therapy.
    Chlebowski RT.
    Clin Breast Cancer; 2013 Jun; 13(3):159-66. PubMed ID: 23228361
    [No Abstract] [Full Text] [Related]

  • 4. Cyclin D-1, interleukin-6, HER-2/neu, transforming growth factor receptor-II and prediction of relapse in women with early stage, hormone receptor-positive breast cancer treated with tamoxifen.
    Muss HB, Bunn JY, Crocker A, Plaut K, Koh J, Heintz N, Rincon M, Weaver DL, Tam D, Beatty B, Kaufman P, Donovan M, Verbel D, Weiss L.
    Breast J; 2007 Jun; 13(4):337-45. PubMed ID: 17593037
    [Abstract] [Full Text] [Related]

  • 5. The impact of hormone receptor status on the clinical efficacy of the new-generation aromatase inhibitors: a review of data from first-line metastatic disease trials in postmenopausal women.
    Buzdar AU, Vergote I, Sainsbury R.
    Breast J; 2004 Jun; 10(3):211-7. PubMed ID: 15125747
    [Abstract] [Full Text] [Related]

  • 6. [Long-term results of adjuvant endocrine therapy for hormone receptor-positive breast cancer].
    Semilgazov VF, Manikhas AG, Semiglazov VV, Bozhok AA, Dashian GA, Ivanov VG, Paltuev RM, Vasil'ev AG, Shchedrin DE, Ermachenkova AM, Nikitina IV, Pen'kov KD, Bessonov AA, Tabagua TT, Kolar'kova VV.
    Vopr Onkol; 2011 Jun; 57(5):567-77. PubMed ID: 22238925
    [No Abstract] [Full Text] [Related]

  • 7. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
    Coates AS, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A.
    J Clin Oncol; 2007 Feb 10; 25(5):486-92. PubMed ID: 17200148
    [Abstract] [Full Text] [Related]

  • 8. [Breast cancer subtypes and their endocrine-metabolic basis; practical aspects].
    Bershteĭn LM, Semiglazov VF.
    Vopr Onkol; 2011 Feb 10; 57(5):559-66. PubMed ID: 22238924
    [No Abstract] [Full Text] [Related]

  • 9. Commentary: optimal adjuvant endocrine therapy of postmenopausal breast cancer.
    Cunnick G, Mokbel K.
    Int J Fertil Womens Med; 2005 Feb 10; 50(5 Pt 1):197-8. PubMed ID: 16468468
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Does estrogen receptor negative/progesterone receptor positive breast carcinoma exist?
    De Maeyer L, Van Limbergen E, De Nys K, Moerman P, Pochet N, Hendrickx W, Wildiers H, Paridaens R, Smeets A, Christiaens MR, Vergote I, Leunen K, Amant F, Neven P.
    J Clin Oncol; 2008 Jan 10; 26(2):335-6; author reply 336-8. PubMed ID: 18182677
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Adjuvant treatment of breast cancer.
    Akerley WL.
    R I Med; 1995 Sep 10; 78(9):250-3. PubMed ID: 7579720
    [No Abstract] [Full Text] [Related]

  • 16. Is fulvestrant more effective than tamoxifen for treating ER-positive breast cancer in postmenopausal women?
    Raina V.
    Nat Clin Pract Oncol; 2004 Nov 10; 1(1):20-1. PubMed ID: 16264793
    [No Abstract] [Full Text] [Related]

  • 17. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
    Viale G, Regan MM, Maiorano E, Mastropasqua MG, Golouh R, Perin T, Brown RW, Kovács A, Pillay K, Ohlschlegel C, Braye S, Grigolato P, Rusca T, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS.
    J Clin Oncol; 2008 Mar 20; 26(9):1404-10. PubMed ID: 18349391
    [Abstract] [Full Text] [Related]

  • 18. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
    Breast International Group (BIG) 1-98 Collaborative GroupSenology Center of Eastern Switzerland, Kantonsspital, St. Gallen, and the Swiss Group for Clinical Cancer Research, Switzerland., Thürlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN, Goldhirsch A.
    N Engl J Med; 2005 Dec 29; 353(26):2747-57. PubMed ID: 16382061
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.